



**1. AMENDMENTS TO THE SPECIFICATION:**


*Please replace the paragraph on page 5, beginning at line 18 with the following amended paragraph:*

Most preferably the compound is selected from the group consisting of compounds **1** to **6**, **10** to **15**, **17**, **19**, **20**, **22**, **25**, **26**, **28**, **30**, **31**, **33** to **37**, **39** to **45**, **47** to **50**, **52** to **58** and **60** to **70** described in provisional PCT international patent application No. PCT/AU02/01427 (which gave rise to United States Patent Appl. Serial No. 10/493,117, published 9/28/06 as 20060217530), including the following compounds:







3




4




5




6




10




11




12




13




14




15




17




19




20




22




25




26




29




30




31




33




34




35




36




37




38




39




41




42




43




44




45




46




57




58




60




61



62



63




In a particularly preferred embodiment, the compound is PMX53 (compound 1), compound 33, compound 60 or compound 45 ~~described therein~~ illustrated *supra*.


***Please replace the paragraph on page 12, beginning at line 4 with the following amended paragraph:***

Compounds 1-6, 17, 20, 28, 30, 31, 36 and 44 disclosed in International patent application No. PCT/AU98/00490 and compounds 10-12, 14, 15, 25, 33, 35, 40, 45, 48, 52, 58, 60, 66, and 68-70 disclosed for the first time in Australian ~~provisional~~ PCT international patent application No. PCT/AU02/01427 have appreciable antagonist potency ( $IC_{50} < 1 \mu M$ ) against the C5a receptor on human neutrophils. PMX53 (compound 17 of PCT/AU98/00490; also identified as compound 1 in PCT/AU02/01427) and compounds 33, 45 and 60 of PCT/AU02/01427 illustrated *infra* are most preferred:







1



33



45



50